From six years ago, a little snippet.
Goldman Sachs asks in biotech research report: ‘Is curing patients a sustainable business model?’
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run.
This is before Covid; before the gene therapy mRNA jabs that people had.
https://www.cnbc.com/2018/04/11/goldman ... model.html